Abstract
When COVID-19 emerged as a global pandemic, the World Health Organization (WHO) recommended a pause in the delivery of neglected tropical disease preventative chemotherapy and surveillance. The Act to End NTDs | East program (Act | East) worked with country neglected tropical disease (NTD) programs to develop, support, and implement guidelines that allowed NTD service delivery and surveillance to resume. This paper examines those adaptations that Act | East made as a program to support numerous countries, over a discrete time period, to resume NTD program operations. This paper also examined how the pause and the resumption of service delivery with new guidelines and standard operating procedures in place affected program operations. Specifically, we examine delays in scheduled mass drug administration and disease surveys, coverage achieved by resumed mass drug administration campaigns, and the impact that COVID-19 had on planning and budgeting. We review which adaptations have been retained in a post-COVID-19 landscape, and which may inform NTD and other global health programs, to better respond in future public health emergencies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This manuscript is made possible by the generous support of the American People through the United States Agency for International Development (USAID)under cooperative agreement No. 7200AA18CA00040 and does not necessarily reflect the views of USAID or the United States Government.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Data presented are programmatic in nature and cloassified as not human subjects research by the RTI IRB
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data presented are the owned by the ministries of health whose countries are included in this analysis. All data included in this paper are used with express permission of the data owners.
